Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer
S.N. Westin(The University of Texas MD Anderson Cancer Center), Robert L. Coleman(Texas Oncology), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Rhys Williams(Cambridge Collaborative (United States)), Stacy L. Moulder(The University of Texas MD Anderson Cancer Center), L Engerman(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Emma McMurtry(AstraZeneca (United Kingdom)), Paul Rugman(AstraZeneca (United Kingdom)), Justin P.O. Lindemann(University Hospital Ostrava), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Kathleen M. Schmeler(The University of Texas MD Anderson Cancer Center), Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Charles Samuel(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), A. Cyriac(The University of Texas MD Anderson Cancer Center), Gordon B. Mills(The University of Texas MD Anderson Cancer Center)
Cited by 16
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
|Cancer Cell|2017|2.1k